Resources
Video DemoTopic
product
Media Type
Illuminator INT100
Bacterial contamination of platelet components, passive vs. active, surveillance, testing and pathogen reduction technologies
Dr. Richard J. Benjamin, MBChB, PhD, FRCPath
Cerus Corporation
Concord, California, USA
Illuminator INT100
Stanford Blood Center – the first blood center of its size to implement pathogen reduction for 100% of platelet components
Stanford Blood Center
California, United States
Illuminator INT100
Experiences of standardized volume, pathogen-reduced, pooled plasma for faster availability of components for transfusion
Ms. Marja-Kaisa Auvinen, MD, PhD
Uppsala University Hospital
Uppsala, Sweden
Illuminator INT100
Overview of the variability in platelet production processes and applied safety measures
Dr. Mohammad R. Abedi, MD, PhD
Örebro University Hospital
Stockholm, Sweden
Illuminator INT100
Case study: impact of pathogen inactivation on outdating rates and supply continuity
Ms. Ragna Landrö, BSc
The Blood Bank
The National University Hospital of Iceland
Reykjavík, Iceland
Illuminator INT100
Case study: enabling double dose methodology on Reveos through pathogen inactivation
Ms. Eleonore Tennby
Cerus Europe B.V.
Amersfoort, the Netherlands
Illuminator INT100
Cryoprecipitate from pathogen reduced concurrent apheresis plasma
Dr. Konrad Rosskopf, MD
Medical University Graz
Graz, Austria
Illuminator INT100
Production and in vitro quality of pooled whole blood derived PI plasma
Dr. sc. nat. David Goslings, MBA
Blood Transfusion Service Zurich
Zurich, Switzerland
Illuminator INT100
Production and in vitro quality of pooled whole blood derived PI plasma
Dr. sc. nat. David Goslings, MBA
Blood Transfusion Service Zurich
Zurich, Switzerland
Illuminator INT100
How pools-of-pools contributes to optimising your PI platelet products
Mr. Jean-Marc Payrat
Cerus Europe B.V.
Amersfoort, the Netherlands
Illuminator INT100
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products Using the INTERCEPT Blood System
Dr. Mohammad R. Abedi, MD, PhD
Örebro University Hospital
Stockholm, Sweden
Illuminator INT100
How to bring bacterial risk control strategies within financial reach
Kathleen Rowe
Sr. Global Health Policy Director
Cerus BV